These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27087201)

  • 21. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bringing Humira (Its Price) Down a Peg.
    Ladika S
    Manag Care; 2019 Jan; 28(1):7-8. PubMed ID: 30883314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.
    Gisondi P; Geat D; Armeni P; Bellinato F; Maurelli M; Girolomoni G
    Expert Opin Biol Ther; 2022 Dec; 22(12):1579-1584. PubMed ID: 35466843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab.
    Velayudhan J; Chen YF; Rohrbach A; Pastula C; Maher G; Thomas H; Brown R; Born TL
    BioDrugs; 2016 Aug; 30(4):339-51. PubMed ID: 27422671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
    Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L
    MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patent litigation could make 2017 no 'dancing' matter.
    Reinke T
    Manag Care; 2016 Dec; 25(12):23-28. PubMed ID: 28121555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira
    Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J
    Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilars in rheumatology: understanding the rigor of their development.
    Goel N; Chance K
    Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Expiry of Humira
    Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
    Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
    [No Abstract]   [Full Text] [Related]  

  • 32. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.
    Liu J; Eris T; Li C; Cao S; Kuhns S
    BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
    Scheinberg M; Castañeda-Hernández G
    Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
    Epstein RA
    Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilar monoclonal antibodies in China: A patent review.
    Liu JW; Yang YH; Wu N; Wei JF
    Bioengineered; 2022 Jun; 13(6):14503-14518. PubMed ID: 35758066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA.
    Gherghescu I; Delgado-Charro MB
    Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33396369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.